UBS AM’s Passage Bio PASG Stock Holding History

UBS AM’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-574	Closed	-$114K	–	2889
2021 Q3	$114K	Hold	574	–	–	﹤0.01%	2720
2021 Q2	$152K	Buy	574 +48	+9%	+$14.9K	﹤0.01%	2726
2021 Q1	$184K	Buy	+526	New	+$225K	﹤0.01%	2566

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM's PASG Position: Q4 2021 in Review

UBS AM sold out of Passage Bio (PASG) in Q4 2021, closing a stake of 574 shares — an estimated $114K sold.

UBS AM first reported a position in PASG in Q1 2021 and held it in 3 quarters. The position peaked at $184K in Q1 2021. 99 funds tracked by Wall St. Rank hold PASG as of Q4 2021.

UBS AM reported no remaining Passage Bio position as of Q4 2021 after selling out during the quarter.
UBS AM sold 574 Passage Bio shares in Q4 2021, an estimated $114K.
UBS AM first reported a position in Passage Bio in Q1 2021 and held it in 3 quarters.
UBS AM's Passage Bio position peaked at $184K in Q1 2021.
99 funds tracked by Wall St. Rank held Passage Bio as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.